November 24, 2016 - By Vivian Park
Chemocentryx Inc Chief Medical Officer and an insider Petrus Bekker a few days ago sold 1,250 company shares worth $10,375 at an avg stock price per share of $8.3. This is not his first insider trade, in the last 30 days, he unloaded another 33,332 shares worth $266,656 USD. A report freely available for review here reveals this insider activity, that was made on 23-11-2016 and was filed with the Security Exchange Commission. Petrus Bekker presently has rights to 53,594 shares which make up about 0.11% of the California-based company’s market cap.
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.08, from 1.11 in 2016Q1. The ratio dived, as 12 funds sold all ChemoCentryx Inc shares owned while 23 reduced positions. 20 funds bought stakes while 19 increased positions. They now own 22.71 million shares or 5.49% less from 24.03 million shares in 2016Q1.
Alliancebernstein Lp reported 31,700 shares or 0% of all its holdings. Fernwood Management Limited Liability Co holds 0.04% or 10,000 shares in its portfolio. Creative Planning accumulated 7,000 shares or 0% of the stock. Iguana Healthcare Ltd Limited Liability Company last reported 150,000 shares in the company. Renaissance Tech Limited Liability Co holds 0% or 69,681 shares in its portfolio. Highbridge Management Ltd Liability Com holds 0% of its portfolio in ChemoCentryx Inc (NASDAQ:CCXI) for 39,966 shares. Tower Research Cap Limited Liability Company (Trc) has 753 shares for 0% of their US portfolio. State Bank Of Montreal Can accumulated 0% or 32,059 shares. Bnp Paribas Arbitrage, a New York-based fund reported 841 shares. Schwab Charles Mgmt Inc last reported 0% of its portfolio in the stock. Teachers Advsrs holds 0% or 37,174 shares in its portfolio. Goldman Sachs has 0% invested in the company for 56,389 shares. Rhumbline Advisers holds 0% of its portfolio in ChemoCentryx Inc (NASDAQ:CCXI) for 25,946 shares. Franklin Resources Inc holds 2.17M shares or 0.01% of its portfolio. Millennium Mngmt Ltd Liability last reported 13,172 shares in the company.
Insider Transactions: Since September 1, 2016, the stock had 0 buys, and 4 selling transactions for $321,704 net activity. LUCAS ROGER C had sold 4,000 shares worth $24,411 on Tuesday, November 1. On Tuesday, November 22 Bekker Petrus sold $10,375 worth of the stock or 1,250 shares.
The stock increased 0.37% or $0.03 during the last trading session, hitting $8.13. About 120,517 shares traded hands. ChemoCentryx Inc (NASDAQ:CCXI) has risen 198.90% since April 22, 2016 and is uptrending. It has outperformed by 193.57% the S&P500.
ChemoCentryx, Inc. is a biopharmaceutical company. The company has a market cap of $387.23 million. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It currently has negative earnings. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.
According to Zacks Investment Research, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.”
Analysts await ChemoCentryx Inc (NASDAQ:CCXI) to report earnings on March, 13.
More news for ChemoCentryx Inc (NASDAQ:CCXI) were recently published by: Streetinsider.com, which released: “Form 4 ChemoCentryx, Inc. For: Nov 22 Filed by: Bekker Petrus” on November 23, 2016. Quotes.Wsj.com‘s article titled: “ChemoCentryx Inc. CCXI (US: Nasdaq)” and published on February 04, 2012 is yet another important article.
ChemoCentryx, Inc. (ChemoCentryx), incorporated on November 8, 1996, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park